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Background: The polycomb group protein, BMI1 plays important roles in chromatin modification, stem cell
function, DNA damage repair and mitochondrial bioenergetics. Such diverse cellular functions of BMI1 could be, in
part, due to post-translational modifications, especially phosphorylation. To date, AKT has been reported as a kinase
that by site specific phosphorylation of BMI1 modulates its oncogenic functions.
Methods: Immunoprecipitation in conjunction with kinase assay and mass spectrometry was used to determine
association with and site specific phosphorylation of BMI1 by CK2α. Functional implications of the BMI1/CK2α axis
was examined in cancer cells utilizing siRNA and exogenous gene expression followed by biochemical and
phenotypic studies. Correlations between expression of CK2α and BMI1 were determined from cell lines and
formalin fixed paraffin embedded tissues representing the normal fallopian tube epithelium and high grade serous
ovarian cancer samples.
Results: Here we report that CK2α, a nuclear serine threonine kinase, phosphorylates BMI1 at Serine 110 as
determined by in-vitro/ex-vivo kinase assay and mass spectrometry. In ovarian cancer cell lines, expression of CK2α
correlated with the phospho-species, as well as basal BMI1 levels. Preventing phosphorylation of BMI1 at Serine 110
significantly decreased half-life and stability of the protein. Additionally, re-expression of the phosphorylatable but
not non-phosphorylatable BMI1 rescued clonal growth in endogenous BMI1 silenced cancer cells leading us to
speculate that CK2α-mediated phosphorylation stabilizes BMI1 and promotes its oncogenic function. Clinically,
compared to normal fallopian tube epithelial tissues, the expression of both BMI1 and CK2α were significantly
higher in tumor tissues obtained from high-grade serous ovarian cancer patients. Among tumor samples, the
expression of BMI1 and CK2α positively correlated (Spearman coefficient = 0.62, P = 0.0021) with each other.
Conclusion: Taken together, our findings establish an important regulatory role of CK2α on BMI1 phosphorylation
and stability and implicate the CK2α/BMI1 axis in ovarian cancer.
Keywords: Post translational modification, Phosphorylation, Kinase assay, Protein stability, Formalin fixed paraffin
embedded tissues (FFPE), Fallopian tube epithelial (FTE) cells, High-grade serous ovarian cancer, Clonal growthBackground
BMI1 is a member of the polycomb repressor complex 1
(PRC1) that in complex with Ring1B catalyzes mono-
ubiquitination of histone H2A (H2AK119) and mediates
gene silencing by regulating chromatin structure. Accu-
mulating evidences have established important roles for
BMI1 as a transcriptional repressor, a regulator of stem* Correspondence: Resham-Bhattacharya@ouhsc.edu
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recently, a mitochondrial role has been described [6, 7].
The importance of BMI1 is further underscored by the
fact that it has been implicated in several different malig-
nancies including ovarian cancer leading to the develop-
ment of clinical small molecule inhibitors [8–10].
The BMI1 protein comprises of 326 amino acids with
an N-terminal RING finger (RF) domain, a middle helix
turn helix (HTH) domain and a C-terminal Proline-Serine
rich (PS/PEST) domain [11]. Post-translational modifica-
tions confer functional diversity to proteins and few such
modifications have been described for BMI1 [3, 5, 12–14].
When phosphorylated by 3 pK (MAPKAP kinase 3),le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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matin resulting in de-repression of targets [13]. Phosphor-
ylation by AKT at Ser 316 of BMI1, triggered its
dissociation from the INK4A/ARF locus resulting in in-
ability to promote tumor growth [12]. On the other hand,
AKT-mediated phosphorylation of BMI1 at Ser 251, 253
and 255 enhanced its oncogenic potential in prostate can-
cer [3]. It is notable that the described phosphorylation
sites reside within the PS/PEST domain, deletion of which
enhances stability of the BMI1 protein [15]. The func-
tional fate of phosphorylated BMI1 thus remains context
and cancer specific.
Like BMI1, the Ser/Thr kinase complex, Casein Kinase
2 (CK2), is involved in various cellular processes affect-
ing clonal growth, survival, apoptosis and DNA damage
repair [16–18]. Similar to BMI1, CK2 is predominantly
present in the nucleus and comprises of a hetero-
tetramer of the catalytic α, α’ and two non-catalytic β
subunits [18]. Notably, expression of both CK2α and
BMI1 is elevated in ovarian cancer and correlates with
poor overall survival [19–21]. Together with predictive
bioinformatics analysis, these evidences prompted us to
evaluate CK2α as a potential kinase in phosphorylating
BMI1. Here, we establish that CK2α is a novel kinase for
BMI1; CK2α phosphorylates BMI1 at Ser110, and this
phosphorylation imparts protein stability contributing to
clonal growth. The identified CK2α-BMI1 liaison is of
clinical significance as high CK2α expression strongly
correlates with the elevated BMI1 protein levels in high
grade serous ovarian cancer tissues. Our results impli-
cate the CK2α/BMI1 axis in ovarian cancer, thus target-
ing it might be potentially beneficial.
Methods
Materials
Lambda phosphatase was purchased from New England Bio
labs (#P0753S). Casein Kinase II Inhibitor I, TBB was pur-
chased from Calbiochem (#218708). CK2α-GST tagged or
CK2α untagged recombinant proteins were purchased from
Signalchem (#C71-10G-10) and Abcam (#90745) res-
pectively. GST-tagged or full-length BMI1 recombinant pro-
teins were purchased from Mybiosource.com
(#MBS717171) and Origene (TP760041) respectively. GST
was purchased from Abcam (#89499). Nonradioactive ATP
(Adenosine triphosphate) was purchased from Thermo-
fischer (# R1441) and radioactive ATP labeled on the
gamma phosphate group with 32P was purchased from
PerkinElmer (#NEG002A250UC). Cyclohexamide, MG132
and AKT inhibitor (Akti) were procured from Sigma
(#R750107) and Calbiochem (#474791; 124018) respectively.
Plasmids and constructs
The plasmids FLAG-BMI1WT (wild-type) construct as
previously described (Fan et. al. 2008), was used togenerate S110A mutant BMI1 FLAG. Quick Change Site
directed mutagenesis kit (Agilent) and the following pair
of primers were used to generate the mutant. Both the
plasmids were sequenced and the integrity was confirmed
before performing experiments. (Forward primer: CTGA
TGCTGCCAATGGCGCTAATGAAG ATAGAGGA; Re-
verse Primer: TCCTCTATCTTCATTAGCGCCATTGG
CAGCATCAG). pZW6 (CK2α) was a gift from David
Litchfield (Addgene plasmid # 27086) [22].
Cell culture and transfection
CP20 cells (developed by sequential exposure of the
A2780 parental cell line to increasing concentrations of
cisplatin) and OV90 cells were kindly gifted by Dr. Anil
Sood, MD Anderson Cancer Center. OVCAR4 was a
kind gift from Dr. Ronny Drapkin, formerly at the Dana-
Farber Cancer Institute, Boston, MA. Immortalized nor-
mal fallopian tube epithelial cells (FTE-188) were a kind
gift from Dr. Jinsong Liu, MD Anderson Cancer Center.
OVSAHO and TKYNU cell lines were obtained from
the Japanese Collection of Research Bioresources Cell
Bank (JCRB). These were routinely cultured in RPMI/
DMEM/MCDB-Med199 (Sigma) supplemented with
10% FBS and 1X penicillin-streptomycin (Gibco, NY,
USA) in a 5% CO2 humidified atmosphere.
Lipofectamine 3000 (Invitrogen) was used for plasmid
transfection and co-transfection with siRNA as per manu-
facturer’s protocol. Gene silencing was performed using
Hiperfect (Qiagen) and 33 picomoles siRNA (scrambled
control, Dharmacon; BMI1 SASI_HS01_00175765 from
Sigma and CK2α siRNA #6389, CST). All experiments
were performed 48–60 h after transfection, unless stated
otherwise.
Protein extraction, determination of protein
concentration, and λ-Phosphatase treatment
Total Cell Lysate was prepared in RIPA (Boston
Bioproducts) or Cell Lytic M (Sigma) compatible with
enzymatic assay and immunoprecipitation.
For the formalin fixed paraffin embedded (FFPE) patient
sample, samples were prepared as previously described
with slight modification [23]. First, samples were deparffi-
nized with 1 ml of xylene; vortexed and stored for 10 min,
followed by centrifugation at 14,000 g × 5 min and then
supernatant was removed. Deparffinization process was re-
peated thrice following which samples were gradiently hy-
drated starting from 100% ethanol followed with 80% and
50% ethanol. After each step the samples were centrifuged
at 14,000 g × 5 min and supernatant was removed. Samples
were stored overnight at 4 °C in 1 ml of DEPC-treated
water and then centrifuged at 14,000 g × 15 min and the
pellet was resuspended in 2% SDS buffer with brief pulse
of sonication (10 s × 3 times), centrifuged (14,000 g ×
15 min) and supernatant collected for downstream assay.
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by Bichonic acid assay (BCA) method using Pierce Kit
(#23225). For most assays 10–30 μg of the lysate
was used.
λ- Phosphatase treatment was performed on 50 μg of
cellular protein incubated with 200units of the
phosphatase at 25 °C for 1 h as per the manufacturer’s
protocol. Reaction was terminated by addition of the
4 × lamelli buffer.
Immunoblotting, immunoprecipitation and kinase
reaction
Immunoprecipitation was performed using Agarose A/G
beads (SCBT-2003) or the Pierce crosslink IP kit (Cat
No # 26147) and cell lysates or immunoprecipitated
proteins were separated by SDS-PAGE and Western im-
munoblotting analysis was performed using standard
protocol as described previously [24]. The cell lysate
were separated on 10 or 12% glycine SDS-PAGE gel or
Phos-tag™SDS-PAGE (for analysis of BMI1 phosphoryl-
ation in a panel of normal and high grade serous
ovarian cancer cells; Wako Cat No # 304-93521). For
Mn2+-Phos-tag SDS-PAGE, 50 μM Phos-tag™ acrylamide
and 2 eq of MnCl2, when added to the resolving part of
10% acrylamide gel provided a convenient method for the
simultaneous analysis of a phosphoprotein isoform(s) and
its non-phosphorylated counterpart [25–27]. Gels were
transferred to PVDF membrane. Membranes were
blocked in 5% non-fat dry milk in TBS with 0.1%
TWEEN-20 (TBST) for 1 h at room temperature followed
by incubation with indicated primary antibodies in TBST
with 5% BSA. Antibodies were purchased from following
venders: Santa Cruz Biotechnology (CK2α #sc-373894,
Akt1/2/3 #sc-8312, p-Akt1/2/3 (Ser473) #sc-7985);
Proteintech (HSP60#66041-1-Ig); Life-Technologies
(BMI1#375400); ABCAM (α − Tubulin #ab4074) and
Sigma (FLAG #F1804, secondary antibodies con-
jugated with horseradish peroxidase IgG Rabbit and
Mouse).
10 μg of required antibody (BMI1 or CK2a) was first
crosslinked to resin using DSS following crosslinking
protocol of the manufacturer (Pierce, crosslinking IP
protocol). Alternately, 1 mg of precleared lysate was incu-
bated with the antibody overnight at 4 °C in spin wheel.
The beads were added to the protein/antibody homogen-
ate on the next day and incubated at 4 °C for 1 h in a spin
wheel. The beads were collected by centrifugation, washed
and suspended in 15 μL IP buffer to be used for radio-
active or nonradioactive kinase assay. Radioactive assay
for CK2α was performed using 10 μg of BMI1/BMI1-GST
with 9 μl of final immunoprecipitate bead in 15 μl reaction
mix respectively containing 50 mM Tris–Cl pH 8.0,
10 mM MgCl2, 50 μM ATP and 5 μCi of [γ-32P] ATP
(3000 Ci/mmol). The reactions were carried out for15 min at 25 °C after which they were stopped by adding
4 × samples loading buffer. The samples were subjected to
SDS-PAGE, the gels were dried and exposed at −80 °C as
required on an X-ray film and developed. Non-radioactive
assay for CK2α used similar protocol with only the radio-
active ATP being replaced by 200 mM of cold ATP and
BMI1/BMI1-GST being used as substrate. The films were
scanned and quantified using Image J software.
Quantitative RT-PCR
Cellular RNA was isolated (Zymo RNA isolation kit, Cat
No: R1050) and 1 μg of total RNA was reverse tran-
scribed to cDNA (iScript cDNA synthesis kit, Bio-Rad).
Total of 1 μl of the 40 μl reverse transcription reaction
were used as template for real-time detection (Bio-Rad
CFX connect) using Sybr green (Bio-Rad) and primers
as described below. Gene expression was quantified for
the tested genes and endogenous control gene 18 S
rRNA. Relative mRNA level was calculated by normaliz-
ing the gene expression levels of tested genes to that of
the control 18 S rRNA gene.
CK2α: Fwd: 5’ TAGGGGGTTGGTATCTCGTG3’;
Rev: 5’ TGATGTAAGCGACCAGCAAG3’
BMI1: Fwd::5’ CCTTCATTGTCTTTTCCGCCC; Rev:5’
AAGTACCCTCCACAAAGCAC 3’
18 S rRNA: Fwd:5’ TCGATGGGCGGCGGAAAATA;
Rev: 5’ TTGGTGAGGTCAATGTCTGCT3’
Clonal growth assay
48 h post transfection 200 single cells of CP20 or OV90
cells in RPMI medium containing 10% FBS were seeded in
the same medium in each well of 6-well plate. After 10 days
(CP20) or 14 days (OV90), the colonies were stained with
the crystal violet solution (0.75% crystal violet, 50% etha-
nol, 0.25% NaCl, 1.57% formaldehyde), imaged using Leica
EZ4HD (Buffalo Grove, IL 60089 USA). 9 images from 3
independent experiments were quantified using Image J
(image processing and analysis in Java, NIH).
Data analysis and statistics
All the experiments were repeated independently at least
3 times and in triplicate where applicable. Data are
expressed as mean ± standard deviation (SD). Compari-
sons between two groups were evaluated using Student’s
t-test with equal/unequal variances. For comparisons
among multiple groups, we performed ANOVA. If the
overall test was significant, we compared each treatment
to control with Dunnett's method for multiple compari-
sons. For densitometry analysis of immunoblots, Image J
software (NIH) was used. BMI1 expression levels were
compared between normal and primary tumor samples
using Wilcoxon rank-sum test. The CK2α detection
rates were compared between the groups (normal vs.
primary tumor) using Fisher’s exact test. Spearman
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between CK2α and BMI1 expression levels among pri-
mary tumor samples. P < 0.05 was considered statistically
significant. All tests were two-sided.
Results
Identification of Casein Kinase 2α, a candidate BMI1
kinase
AKT has been identified as the predominant kinase
phosphorylating BMI1 on Ser 251, 253, 255 and 316 re-
spectively, resulting in its altered cellular activity [3, 12].
However, inhibition of AKT by specific inhibitors (AKTi)
reduced but did not eliminate the characteristic
phospho-bands of BMI1 in ovarian cancer cells, CP20
and OV90 (Fig. 1a). That the slower migrating species
represented phosphorylated form of BMI1 (Fig. 1a) was
confirmed by λ-phosphatase treatment [15]. This suggests
that in ovarian cancer cells additional kinases might be in-
volved in phosphorylating BMI1. Stringent bioinformatics
analysis (NetPhos2.0 Server [28], cutoff <0.9) of the BMI1
protein sequence revealed nine potential sites of phos-
phorylation (Table 1) including Ser 253, 255 and 316 that
were previously described [3, 12]. Interestingly, all of the
previously reported phosphorylation sites of BMI1 lieFig. 1 Expression and regulation of BMI1 and CK2α in ovarian cancer cells.
with λ-Phosphatase but not with AKT inhibitor. OV90 and CP20 cells were
extracted from the vehicle treated cells (C) were further subjected to λ-pho
Phospho-AKT (Serine 473) were determined in the C, λ-P and AKTi treated
BMI1 bands that were removed on phosphatase treatment is considered a
head whereas the basal BMI1 is indicated by the closed arrow head. b Exp
Protein expression was determined in 4 cell lines representing high grade
CP20 and compared to the normal Fallopian Tube Epithelial Cells (FTE188).
represent phospho species of BMI1 and basal BMI1 respectively. c-d Effect
transfected with scrambled siRNA (siCTL) or siRNA against the CK2α gene (
immunoblotting. d Relative mRNA expression of BMI1 and CK2α were dete
endogenous control. Values represent mean fold change (± standard devia
phospho species of BMI1 and basal BMI1 respectively. e Effect of CK2α ove
and 24 h post transfection the expression of BMI1 and CK2α were determin
phospho species of BMI1 and basal BMI1 respectivelywithin the PS/PEST domain (236–326 amino acids), dele-
tion of which increases half-life of the protein [15]. Inter-
rogation of these phosphorylation sites with KinasePhos2
[29] analysis (Table 1) predicted previously reported
kinases such as AKT [3, 12], as well as novel candidate
kinases such as Ataxia Telangiectasia Mutated (ATM) and
Casein Kinase II (CK2) (Table 1). While ATM/ATR
dependent recruitment of BMI1 to sites of DNA damage
has been reported [4], any association with CK2 remains
unknown.
CK2 is a serine-threonine kinase comprising of two
catalytic (α, α') and two regulatory (β) subunits. CK2 is up-
regulated in major lethal malignancies where its expres-
sion correlates with poor overall survival [16, 18, 19].
Interestingly of these subunits, high levels of CK2α corre-
lated with poor overall survival in ovarian cancer [19].
Using immunoblotting, we determined that CK2α levels
were significantly elevated in ovarian cancer cell lines
compared to the non-malignant Fallopian Tube Epithelial
(FTE188) cells (Fig. 1b). Since BMI1 is reportedly phos-
phorylated by AKT, we determined the expression of ac-
tive AKT (Phospho AKT-S473) in these cell lines. With the
exception of OV90, AKT was significantly phosphorylated
in all the cancer cell lines compared to FTE188 (Fig. 1b).a Slow migrating phospho-BMI1 bands were reduced upon treatment
treated with 5 μM AKT inhibitor (AKTi) or vehicle (C) for 15 h. Protein
sphatase (λ-P) treatment or left untreated. Expression of BMI1 and
cells. α-Tubulin and AKT were used as a loading control. Slow migrating
s the phospho species of BMI1 and is indicated by the open arrow
ression of BMI1, CK2α, and AKT (S473) in a panel of ovarian cancer cells.
serous ovarian cancer (TYKNU, OVSAHO and OV90) or cisplatin resistant
α-Tubulin and AKT served as a loading. Open and closed arrow heads
of CK2α knockdown on BMI1. c OV90 and CP20 cells were either
siCK2α) and expression of BMI1, RING1A and CK2α were determined by
rmined by RT-qPCR. Gene expression of 18 s rRNA was used as an
tion) over control (siCTL). Open and closed arrow heads represent
rexpression on BMI1. FTE188 cells were transfected with CK2α plasmid
ed by immunoblotting. Open and closed arrow heads represent
Table 1 Bioinformatics analysis of the potential phospho sites
on BMI1 protein sequence
Scorea Sequencea Siteb Predicted kinase
0.994 KFLRSKMDI S181 PKB/ATM/Aurora/MAPK
0.993 LESDSGSDK S253 ATM/PLK1/CK2
0.991 PRKSSVNGS S316 PKB/ATM/Aurora/IKK/CAMK/PLK1
0.987 SDSGSDKAN S255 ATM/Aurora/CDK
0.987 RPRKSSVNG S315 ATM/Aurora/IKK/CAMK
0.984 DKANSPAGG S260 ATM/Aurora/PLK1/MAPK/CK1
0.955 TPVQSPHPQ S281 ATM/Aurora/MAPK/CDK/CK1
0.951 AANGSNEDR S110 ATM/CK2
0.918 YLETSKYCP S50 ATM
The data derived from NetPhos2.0 server and KinasePhos 2 are indicated by
a and b respectively
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present in all the cancer cell lines including OV90 that
expressed minimal phospho-AKT, thereby implicating
other kinases in phosphorylation of BMI1. Since the ex-
pression of CK2α correlated with the phospho-species of
BMI1, we next determined if altering cellular levels of
CK2α affected phosphorylation of BMI1. Silencing CK2α
by siRNA significantly reduced both phospho-species as
well as basal BMI1 levels in CP20 and OV90 cells (Fig. 1c).
However the PRC1 complex partner of BMI1, RING1A
levels remained unchanged (Fig. 1c). Subsequently we
confirmed that in CK2α silenced cells, reduction in basal
BMI1 level was not due to decreased transcription thus
implicating post-translational events (Fig. 1d). These ob-
servations were further complemented by expressing
CK2α in FTE188 cells that resulted in enhanced basal ex-
pression as well as phosphorylation of BMI1 (Fig. 1e).Fig. 2 BMI1 is a substrate of CK2α. a Co-precipitation of BMI1 with CK2α. R
CK2α antibodies crosslinked with the agarose resin and immunoprobed with C
BMI1. In vitro kinase assay was performed with 400nM CK2α, 200nM or 400nM
presented.. Reaction mixture without substrate (lane 1), only GST protein (lane2)
negative controls. c Kinase assay with immunoprecipitated (IP) endogenous CK2
agarose A/G beads, the beads was washed and incubated in a kinase assay buf
or absence of the specific CK2 inhibitor TBB. A representative autoradiograph is
in the left panel by immunoblotting a small fraction of the IPed beads with CTogether these results suggest that CK2α might poten-
tially phosphorylate BMI1 and directly or indirectly regu-
late its post translational expression.
CK2α phosphorylates BMI1
To determine if BMI1 is a direct substrate of CK2α, we
performed reciprocal co-immunoprecipitation of en-
dogenous BMI1 and CK2α using covalently cross-linked
antibodies to protein A/G agarose beads. BMI1 and
CK2α co-precipitated from lysates of both CP20 and
OV90 cells (Fig. 2a), indicating that BMI1 might be a
novel phosphorylation substrate of CK2α.
To confirm these observations, we performed an
in vitro kinase assay using purified CK2α, GST-tagged
BMI1 and [γ − 32P] ATP. The autoradiograph clearly
demonstrated that BMI1 was phosphorylated by CK2α
(Fig. 2b). Additionally, as previously reported [30],
autophosphosphorylation of CK2α was also observed
(Fig. 2b). To further confirm these observations we first
immunoprecipitated CK2α from cellular lysates of CP20
cells using antibody-conjugated agarose beads (Fig. 2c-left
panel). Equal amount of these agarose beads were incu-
bated with recombinant BMI1 and [γ − 32P] ATP either in
presence or absence of different concentrations of the
CK2 inhibitor, TBB (4,5,6,7-tetrabromobenzotriazole) [31].
The autoradiograph clearly demonstrated that BMI1 was
phosphorylated by CK2α and the signal significantly
diminished with TBB (Fig. 2c-right panel). Together these
results demonstrate that CK2α phosphorylates BMI1.
CK2α phosphorylates BMI1 at S110
To determine the potential site/s on BMI1 that are
phosphorylated by CK2α, full-length purified BMI1 waseciprocal immunoprecipitation (IP) assay was performed with BMI1 and
K2α and BMI1 antibodies respectively. b In vitro kinase assay with CK2α and
BMI1-GST and radioactive ATP and representative autoradiograph image is
, without enzyme (lane 3), and enzyme with GST only (lane 4) served as
α and purified BMI1. CK2α was immunoprecipitated from CP20 cells using
fer supplemented with purified BMI1-GST and radiolabeled ATP, in presence
provided in the right panel. Efficient Immunoprecipitation is demonstrated
K2α antibody
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absence of purified CK2α and non-radioactive ATP and
then analyzed by mass spectrometry (MS). 19% of the
detected BMI1 peptides were phosphorylated at Ser110
compared to none without CK2α as shown in the
phosphopeptide spectrum (Fig. 3a and Additional file 1:
Figure S1). The extracted ion chromatogram for the
peptide is shown in the inset of Fig. 3a. By site-directed
mutagenesis of the FLAG tagged wild-type BMI1 (WT)
construct, we generated a S110A mutant and expressed
these constructs in CP20 cells. Immunoblotting and
densitometric analysis demonstrated that comparable
expression could be achieved by transfection 1.5 μg of
WT and 2 μg of the S110A-BMI1 mutant (Mut-BMI1)
constructs respectively (Fig. 3b). Next, WT or Mut-
BMI1 was immunoprecipitated using anti-FLAG anti-
body conjugated to protein A/G agarose beads (Fig. 3c,
left panel). Equal amount of beads were incubated with
full-length GST-tagged CK2α and [γ − 32P] ATP for the
in vitro kinase assay. Autoradiograph signals were ob-
tained with WT-BMI1 but not with Empty vector (EV)
control or with the Mut-BMI1 (Fig. 3c, right panel).
Together these results indicate that BMI1 is phosphory-
lated by CK2α at the S110 residue.
Mutation at S110 residue decreases half-life of BMI1
Modulation of cellular CK2α levels impacted not only
BMI1 phosphorylation but also total protein levels
(Fig. 1c-d). In addition, though the plasmid backbones
were identical we consistently observed lower expression
of S110A compared to wild-type BMI1 (Fig. 3b) suggest-
ing issues with stability of the mutant (non-phosphoryla-
table) protein. To investigate this possibility, the half-life
of the FLAG tagged WT and S110A-BMI1 was deter-
mined in CP20 cells using 100 μg/ml cyclohexamide
(CHX). As evidenced by immunoblotting and densitom-
etry, WT-BMI1 had a half-life of ~23 min while S110A
with a half-life of ~11 min degraded faster (Fig. 4a). Prior
studies have reported a half-life of ~25–30 min for WT-
BMI1 that is specifically degraded by the 26S proteasome-
mediated pathway [15]. To determine if decreased sta-
bility of mutant BMI1 was due to proteasome-
mediated degradation, we treated plasmid transfected
CP20 cells with the proteasome inhibitor MG132
(10 μM) for the indicated times. Compared to the
wild-type protein, consistently more S110A-BMI1 ac-
cumulated after treatment with MG132 suggesting that
the mutation and thereby lack of phosphorylation ren-
dered the protein less stable and more amenable to
degradation by the proteasome (Fig. 4b). Similarly,
compared to the control more accumulation of en-
dogenous BMI1 could be observed in the MG132
treated CK2α silenced cells (Fig. 4c) further supporting
that phosphorylation at S110 affects stability of BMI1.Importance of the CK2α/BMI1 axis in ovarian cancer
BMI1 confers clonal self-renewal property to cells.
Therefore using clonal growth assays, we determined the
effect of WT or S110A-BMI1 in OV90 and CP20 cells.
Simultaneously, endogenous BMI1 was silenced by a
3'UTR targeted siRNA and comparable levels of WT or
S110A-BMI1 was expressed in these cells. Significant
knockdown of endogenous BMI1 by siRNA and re-
expression of the FLAG tagged WT and S110A-BMI1
was confirmed by immunoblotting (Fig. 5a). Compared
to the control, significant decrease in clonal growth was
observed in the BMI1 silenced cells (~55% in OV90
and ~45% in CP20; Fig. 5b-c). Re-expression of WT-BMI1
almost completely rescued clonal growth in endogenous
BMI1 silenced cells while the S110A-BMI1 had no effect
(Fig. 5b-c).
Based on these results we posited that if CK2α medi-
ated BMI1 phosphorylation led to protein stability, then
a correlation between CK2α and BMI1 protein levels
would be expected in ovarian cancer clinical specimens.
Therefore, we analyzed BMI1 and CK2α levels in a panel
of twenty high-grade serous ovarian tumors and two
normal fallopian tube epithelial (FTE) tissues [32] by im-
munoblotting. BMI1 expression was significantly higher
in primary tissues (p = 0.0398) and CK2α was detected
in a significantly higher proportion of primary tissues
(p = 0.013). Remarkably within the tumor samples, signifi-
cant correlation between CK2α and BM11 expression was
observed (Fig. 5d, Spearman correlation coefficient is 0.62,
p = 0.0021). While patients with higher expression of both
BMI1 and CK2α showed a trend towards shorter pro-
gression free survival, the data did not reach statistical sig-
nificance likely due to the limited sample size (Additional
file 1: Figure S2). Together, these results demonstrate that
phosphorylation of BMI1 at Ser110 by CK2α is important
for both stability and functionality of the protein.
Discussion
Given the important role of BMI1 in cancer biology it is
important to investigate its post-translational modifications
because they confer functional diversity to proteins and
few such modifications of BMI1 have been previously de-
scribed. Here we report that CK2α by phosphorylating at
the Ser110 residue regulates stability of the BMI1 protein.
Interestingly, all of the previously reported phosphor-
ylation sites of BMI1 lie within the C-terminal PS/PEST
domain (236–326 amino acids) and involve AKT [3, 12].
Though bioinformatics analysis predicted a number of
potential kinases that could phosphorylate BMI1, we
focused on CK2α because the hetero-tetrameric CK2
complex with constitutive kinase activity is predomin-
antly present in the nucleus like BMI1. Also, ovarian
cancer cells that expressed CK2α but minimally acti-
vated AKT maintained phosphorylated species of BMI1.
Fig. 3 Identification of amino acid residue on BMI1, phosphorylated by CK2α: a Kinase assay and Mass-spectrometric analysis. Purified BMI1 and
CK2α were allowed to react in a kinase assay buffer supplemented with nonradioactive ATP. The reaction was terminated after 30 min and the
sample was sent for mass spectrometric analysis. The spectrum of the BMI1 phospeptide is presented with the extracted ion chromatogram for
the peptide with phosphate shown in the inset (indicated by #). b Relative expression of WT and mutant BMI1: Phospho mutant BMI1 with
substitution of Serine at 110 with Alanine (S110A mutant BMI1) was generated using the wild-type BMI1 (WT-BMI1) as a template for site directed
mutagenesis. CP20 cells were transfected with increasing DNA concentration (0.5 μg -2 μg) of wild-type or mutant BMI1 and 30 h post transfection
samples were harvested for immunoblotting with FLAG antibody. HSP60 is used as a loading control. Right panel shows a representative immunoblot
for the expression of the WT and Mut-BMI1. To determine DNA concentration required to achieve comparable expression between WT and Mut-BMI1,
a densitometry analysis of the bands was performed using Image J software (NIH, Bethesda, MD), and the graph was generated by plotting fold
intensity vs DNA concentration. The broken line indicates equivalent expression level of WT and Mut-BMI1. c Kinase assay with Mutant BMI. CP20 cells
were transfected with EV (2 μg), WT (1.5 μg) and Mut-BMI1 (2 μg) and 30 h post transfections cells were harvested for immunoprecipitation with
FLAG antibody and agarose beads. A fraction of the agarose beads were processed for immunoblotting to ensure efficient immunoprecipitation and
depicted as an immunograph in the left panel. The right panel shows radiograph for kinase assay reaction with the immunoprecipitated beads and in
presence/absence of Purified GST-CK2α and radiolabeled ATP
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co-precipitated with BMI1. Using in vitro kinase assays
and Mass spectrometry we confirmed that CK2α phos-
phorylates BMI1 at the Ser110 residue.
Prior reports indicate that protein turnover of BMI1 is
regulated by βTrCP recognizing a degron motif within the
PS/PEST domain, where all the previously described phos-
phorylation sites reside [33]. Deletion of the PS/PEST do-
main thus increases the half-life and stability of the protein
[15]. Other mechanisms of BMI1 stability include direct as-
sociation with the FAL1 long noncoding RNA resulting inincreased clonogenicity and tumorigenicity in an ovarian
cancer model [34]. Phosphorylation can differentially regu-
late proteosomal degradation [35–38]. Our results suggest
that phosphorylation at Ser110 by CK2α stabilizes BMI1
because mutation to non-phosphorylatable alanine signifi-
cantly reduces half-life of the protein resulting in increased
accumulation upon addition of MG132 indicating proteaso-
mal degradation. Phosphorylation-mediated alteration in
protein conformation resulting in reduced ubiquitination or
enhanced interaction with other stabilizing proteins, akin to
many other cellular proteins [39, 40] may be envisioned.
Fig. 4 Phospho-mutant BMI1 is intrinsically unstable. a Determining the half-life of Wild-type (WT) and S110A mutant BMI1 (Mut-BMI1). The
half-life of wild-type and mutant BMI1 in CP20 cells expressing the respective protein was determined by blocking synthesis of new proteins using
100 μg/ml CHX for different time points (0–45 min) and the rate of BMI1 degradation was determined by western blot analysis of FLAG(BMI1) with
HSP60 serving as a loading control. Residual BMI1 protein after each time point was normalized to HSP60 using densitometry measurements. The
time-dependent decrease of BMI1 was quantified to determine the half-life and is graphically represented in the right panel. The densitometry analysis
was performed using Image J software (NIH, Bethesda, MD), and the graph was generated by plotting % residual protein vs time of CHX treatment.
b Effect of proteosomal inhibition on Wild-type (WT) and S110A mutant BMI1 (Mut-BMI1). 30 h post transfection, CP20 cells were treated with 10 μM
MG132, for different time points (0–120 min) to determine the accumulation of WT or mutant BMI1. Left panel represents the immunoblots for FLAG
and HSP60 and quantification of the accumulated proteins by densitometry analysis of signal present in respective lanes (normalized to the individual
HSP60) is graphically represented in the right panel. c Effect of proteosomal inhibition on BMI1 protein accumulation in CK2α silenced cells. CP20 cells
were transfected with scrambled siRNA (siCTL) or siRNA against CK2α (siCK2α) and 48 h post transfection, cells were treated with 10 μM MG132, for
different time points (0–120 min) to determine the effect of silencing CK2α on MG132 induced accumulation of endogenous BMI1. siCTL or siCK2α
transfected cells were harvested after each time point and analyzed for accumulation of the endogenous BMI1 protein by western blot analysis and
using HSP60 as a loading control (bottom left panel). Efficient silencing by CK2α siRNA was also determined (top left panel). The accumulated proteins
were quantified by densitometry analysis of signal present in respective lanes and by normalizing it to the individual HSP60 and graphically represented
in the right panel
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Our results, generally, demonstrate a correlation be-
tween expression of CK2α and phosphorylated BMI1 in
ovarian cancer cell lines and patient tissues. Interestingly
previous reports suggest that expression of both CK2α
and BMI1 is elevated in ovarian cancer and correlates
with poor overall survival (19, 20). Also, in vivo studies
in mice bearing A2780-xenografts, confirmed that anti-
tumor efficacy could be enhanced by combining the
CK2 inhibitor with cisplatin, carboplatin, or gemcitabine
[41]. However, in these studies, the expression of BMI1
was not determined. We find that re-expression of
phosphorylatable but not non-phosphorylatable BMI1
rescues clonal growth in endogenous BMI1 silencedovarian cancer cells leading us to speculate that CK2α-
mediated phosphorylation stabilizes BMI1 and promotes
its oncogenic function.Additional file
Additional file 1: Figure S1. The spectrum obtained from MS analysis of
Phospheptide of BMI1 (DFYAAHPSADAANGS#NEDRGEVADEDKR). Figure S2.
Association between BMI1+ CK2α (categorized into “high BMI1 + high CK2α”
vs “others”) and patient survival (PFS). Expression of CK2α and BMI1 in the
ovarian cancer patient samples (N= 20) were determined by immunoblotting,
quantified by densitometry analysis as described in the “methods section” and
grouped as high BMI1/high CK2α expressers versus all others. While PFS was
worse in the high BMI1 + high CK2α group, the result was not statistically
significant (P= 0.4), possible due to small sample size. (DOCX 78 kb)
Fig. 5 Physiological and clinical relevance of CK2α mediated BMI1 phosphophorylation: a Re-expression of exogenous BMI1 in a BMI1 silenced
cells. CP20 and OV90 cells are co transfected with FLAG tagged plasmids for WT (wild-type) -BMI1or Mut (S110A) -BMI1 or EV (empty vector) along
with siBMI1 (siRNA against the 3’UTR of the BMI1) or siC (scrambled siRNA). Expression of the exogenous and the endogenous BMI1 were probed
by immunoblotting with the FLAG and BMI 1 antibodies respectively. HSP60 is used to indicate equal protein loading. b, c Clonal growth. CP20
and OV90 cells were co-transfected with plasmid and siRNA as described in (A) and 48 h post transfection, cells were recounted and plated as
single cells in 35 mm dishes. After 10 (CP20) or 14 (OV90) days, colonies were stained with crystal violet, imaged and 9 images from 3 independent
experiments were quantified using ImageJ in a blinded fashion. Top panel depicts a graphical representation of data presented as Relative clonal
growth against control (siC + EV) which is considered as 1. Lower panel shows representative images of the colonies. P < 0.05 is considered statistically
significant and represented with * (SiC + EV vs EV + siBMI1); # (EV + siBMI1 vs WT-BMI1 + siBMI1); @ (WT-BMI1 + siBMI1 vs Mut-BMI1 + siBMI1).
d Coexpression of CK2α and BMI1 in primary tissues. Protein was extracted from the 20 primary tumors (T1 to T20) and 2 normal fallopian tube
epithelial (FTE 1, 2) samples as described in the material and methods section and were quantified by densitometry analysis using Image J. Expression
of CK2α and BMI1 were individually normalized to their respective α-tubulin levels. Left Panel represents immunograph for BMI1 and CK2α expression
in primary tissues. Right panel represents scatterplot of CK2α vs. BMI1 with overlaid linear regression line among tumor tissue samples (N = 19).
Spearman correlation coefficient is 0.62 (p = 0.0021)
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